Sandra Valenzuela‐Ubiña
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sandra Valenzuela‐Ubiña has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Mario Linares‐Barrios
Unidad de Gestión Clínica de Dermatología Médico‐Quirúrgica y Venereología Hospital Universitario Puerta del Mar Cádiz Spain
4 shared publicationsDavid Jiménez-Gallo
Puerta Del Mar Univ Hosp, Unidad Gest, Clin Dermatol Med Quirurg & Venereol, Cadiz, Spain
2 shared publicationsDavid Jiménez‐Gallo
Unidad de Gestión Clínica de Dermatología Médico‐Quirúrgica y Venereología Hospital Universitario Puerta del Mar Cádiz Spain
2 shared publications- Irene Navarro‐Navarro
Unidad de Gestión Clínica de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Puerta del Mar, Cádiz, Spain
2 shared publications Isabel Villegas‐Romero
Unidad de Gestión Clínica de Dermatología Médico‐Quirúrgica y Venereología Hospital Universitario Puerta del Mar Cádiz Spain
2 shared publicationsMario Linares-Barrios
Puerta Del Mar Univ Hosp, Unidad Gest, Clin Dermatol Med Quirurg & Venereol, Cadiz, Spain
2 shared publications
Latest Publications
- 24 April 2022
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 20 (6) , 881-884
Recurrent urticarial plaques in an old man
- 24 April 2022
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 20 (6) , 881-884
Recurrent urticarial plaques in an old man
- Open Access
- 1 October 2021
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 112 (9) , 853-856
Erupción pitiriasis rosada-like inducida por imatinib en paciente con tumor del estroma gastrointestinal
- 1 October 2021
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 112 (9) , 853-856
Open AccessErupción pitiriasis rosada-like inducida por imatinib en paciente con tumor del estroma gastrointestinal
- 9 June 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , E408-E410
Miliaria crystallina induced by idarubicin and all‐trans‐retinoic acid: Two case reports
Miliaria crystallina is a benign, self‐limiting disorder of the eccrine sweat glands characterized by the obstruction of the sweat ducts, which leads to secondary sweat retention into stratum corneum. We present two patients with MC during treatment with idarubicin and all‐trans‐retinoic acid (ATRA) for acute promyelocytic leukaemia (APL). Anthracyclines can be excreted through sweat and induce MC through exfoliation. The use of idarubicin in combination with ATRA would favour the process of producing a peeling effect. Reports of MC associated with idarubicin and ATRA are scarce. Recognizing this benign entity and its triggers will help to differentiate it from other skin reactions, improving the management of patients by avoiding unnecessary studies and treatments.
- 9 June 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , E408-E410
Miliaria crystallina induced by idarubicin and all‐trans‐retinoic acid: Two case reports
Miliaria crystallina is a benign, self‐limiting disorder of the eccrine sweat glands characterized by the obstruction of the sweat ducts, which leads to secondary sweat retention into stratum corneum. We present two patients with MC during treatment with idarubicin and all‐trans‐retinoic acid (ATRA) for acute promyelocytic leukaemia (APL). Anthracyclines can be excreted through sweat and induce MC through exfoliation. The use of idarubicin in combination with ATRA would favour the process of producing a peeling effect. Reports of MC associated with idarubicin and ATRA are scarce. Recognizing this benign entity and its triggers will help to differentiate it from other skin reactions, improving the management of patients by avoiding unnecessary studies and treatments.
- Open Access
- 12 April 2021
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 88 (5) , 645
Striate palmoplantar keratoderma of Brünauer-Fuhs-Siemens
- 12 April 2021
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 88 (5) , 645
Open AccessStriate palmoplantar keratoderma of Brünauer-Fuhs-Siemens
- 26 February 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 435-436
Psoriasis over healed inflammatory linear verrucous epidermal nevus: Wolf´s isotopic response
- 26 February 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 435-436
Psoriasis over healed inflammatory linear verrucous epidermal nevus: Wolf´s isotopic response
- 1 November 2020
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (6) , e14383
Oral whitish lichenoid lesions after treatment with intravenous immunoglobulins
Click on the article title to read more.
- 1 November 2020
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (6) , e14383
Oral whitish lichenoid lesions after treatment with intravenous immunoglobulins
Click on the article title to read more.
- 6 September 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (3) , E53
Infantile bullous pemphigoid following serogroup B meningococcal vaccination
- 6 September 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (3) , E53
Infantile bullous pemphigoid following serogroup B meningococcal vaccination
- 1 July 2020
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (4) , e13692
Elastosis perforans serpiginosa induced byd-penicillamine treated with cyclosporine and allopurinol
Elastosis perforans serpiginosa (EPS) is a rare condition within the group of perforating dermatoses. It is characterized by the synthesis of anomalous elastic fibers that are eliminated through perforating channels (transepidermal elimination). It is classified into three subtypes. One of them is drug-induced by prolonged treatment withd-penicillamine. This drug is a heavy metal chelator used to treat diseases such as rheumatoid arthritis, cystinuria, and Wilson's disease. Years of treatment withd-penicillamine at high doses are required for developing EPS, with occasional slow regression after drug withdrawal. There is no established treatment for EPS, with described cases using various treatment options such as corticoids, retinoids, tazarotene, cryotherapy, imiquimod, photodynamic therapy, electrosurgery, and CO2 laser among others with inconsistent results. We present a case of EPS induced byd-penicillamine with favorable response to cyclosporine and allopurinol in a patient with a history of Wilson's disease since childhood. They maybe considered as possible therapeutic options not described so far for an entity with variable response to current treatments. We highlight the extensive involvement of the case with progression, despite the suspension ofd-penicillamine and failure to previous treatments with photodynamic therapy and retinoids.
- 1 July 2020
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (4) , e13692
Elastosis perforans serpiginosa induced byd-penicillamine treated with cyclosporine and allopurinol
Elastosis perforans serpiginosa (EPS) is a rare condition within the group of perforating dermatoses. It is characterized by the synthesis of anomalous elastic fibers that are eliminated through perforating channels (transepidermal elimination). It is classified into three subtypes. One of them is drug-induced by prolonged treatment withd-penicillamine. This drug is a heavy metal chelator used to treat diseases such as rheumatoid arthritis, cystinuria, and Wilson's disease. Years of treatment withd-penicillamine at high doses are required for developing EPS, with occasional slow regression after drug withdrawal. There is no established treatment for EPS, with described cases using various treatment options such as corticoids, retinoids, tazarotene, cryotherapy, imiquimod, photodynamic therapy, electrosurgery, and CO2 laser among others with inconsistent results. We present a case of EPS induced byd-penicillamine with favorable response to cyclosporine and allopurinol in a patient with a history of Wilson's disease since childhood. They maybe considered as possible therapeutic options not described so far for an entity with variable response to current treatments. We highlight the extensive involvement of the case with progression, despite the suspension ofd-penicillamine and failure to previous treatments with photodynamic therapy and retinoids.
- 11 June 2020
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (2) , 1159-1162
Effectiveness of ustekinumab for moderate-to-severe hidradenitis suppurativa: a case series
Dear Editor,Hidradenitis suppurativa (HS) presents a treatment challenge for dermatologists. Drugs as antibiotics, corticosteroids, retinoids and immunosuppressants are among the conventional thera...
- 11 June 2020
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (2) , 1159-1162
Effectiveness of ustekinumab for moderate-to-severe hidradenitis suppurativa: a case series
Dear Editor,Hidradenitis suppurativa (HS) presents a treatment challenge for dermatologists. Drugs as antibiotics, corticosteroids, retinoids and immunosuppressants are among the conventional thera...